Galloyl cyclic-imide derivative CH1104I inhibits tumor invasion through suppressing matrix metalloproteinase activity

Anti-Cancer Drugs

Volumn 19, Issue 10, 2008, Pages 957-965

  Chen, Ming Hui ^a   Cui, Shu Xiang ^b   Cheng, Yan Na ^a   Sun, Li Rui ^a   Li, Qian Bin ^a   Xu, Wen Fang ^a   Ward, Stephen G ^c   Tang, Wei ^a,d   Qu, Xian Jun ^a  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG FIRST MEDICAL UNIVERSITY   (China)

^c University of Bath   (United Kingdom)

^d UNIVERSITY OF TOKYO   (Japan)

Author keywords

CH1104I; Galloyl cyclic imide derivative; Invasion and metastasis; Matrix metalloproteinases

Indexed keywords

CH 1104 I; GELATINASE A; GELATINASE B; IMIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; C57BL 6 MOUSE; CANCER CELL CULTURE; CANCER INVASION; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFICACY; DRUG STRUCTURE; ENZYME REPRESSION; HUMAN; HUMAN CELL; LEWIS CARCINOMA; METASTASIS; METASTASIS INHIBITION; MOUSE; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS; BENZAMIDES; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; GELATINASES; HUMANS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASES; NEOPLASM INVASIVENESS; PIPERIDONES; PROTEASE INHIBITORS;

EID: 54249100175     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e328313e15b     Document Type: Article

References (28)

1. Bogenrieder T, Herlyn M. Axis of evil: molecular mechanisms of cancer metastasis. Oncogene 2003; 22:6524-6536.
2. Hornebeck W, Emonard H, Monboisse JC, Bellon G. Matrix-directed regulation of pericellular proteolysis and tumor progression. Semin Cancer Biol 2002; 12:231-241.
3. Liotta LA, Stetler-Stevenson WG, Steeg PS. Cancer invasion and metastasis: positive and negative regulatory elements. Cancer Invest 1991; 9:543-551.
4. Hamacher S, Matern S, Roeb E. Extracellular matrix - from basic research to clinical significance. An overview with special consideration of matrix metalloproteinases. Dtsch Med Wochenschr 2004; 129:1976-1980.
5. Määtta M, Talvensaari-Mattila A, Turpeenniemi-Hujanen T, Santala M. Matrix metalloproteinase-2 (MMP-2) and -9 (MMP-9) and their tissue inhibitors (TIMP-1 and TIMP-2) in differential diagnosis between low malignant potential (LMP) and malignant ovarian tumours. Anticancer Res 2007; 27:2753-2758.
6. Sillanpää S, Anttila M, Suhonen K, Hämäläinen K, Turpeenniemi-Hujanen T, Puistola U, et al. Prognostic significance of extracellular matrix metalloproteinase inducer and matrix metalloproteinase 2 in epithelial ovarian cancer. Tumour Biol 2007; 28:280-289.
7. Li QB, Fang H, Xu WF. Novel 3-galloylamide-N′-substituted-2, 6-piperidinedione-N-acetamide peptidomimetics as metalloproteinase inhibitors. Bioorg Med Chem Lett 2007; 17:2935-2938.
8. Wang JL, Xu WF. The preparation of novel L-iso-glutamine derivatives as potential antitumor agents. J Chem Res Synop 2003; 12:789-791.
9. Cui Y, Lu C, Kang A, Liu L, Tan S, Sun D, et al. Nordihydroguaiaretic acid restores expression of silenced E-cadherin gene in human breast cancer cell lines and xenografts. Anticancer Drugs 2008; 19:487-494.
10. Baragi VM, Shaw BI, Renkiewicz RR, Kuipers PJ, Welgus HG, Mathrubutham M, et al. A versatile assay for gelatinases using succinylated gelatin. Matrix Biol 2000; 19:267-273.
11. Qu X, Yuan Y, Xu W, Chen M, Cui S, Meng H, et al. Caffeoyl pynolidine derivative LY52 inhibits tumor invasion and metastasis via suppression of matrix metalloproteinase activity. Anticancer Res 2006; 26:3573-3578.
12. Jeon JH, Shin DM, Cho SY, Song KY, Park NH, Kang HS, et al. Immunocytochemical detection of HPV16 E7 in cervical smear. Exp Mol Med 2007; 39:621-628.
13. 2 in vitro. Pharmacol Res 2005; 52:174-182.
14. 2-terminal kinase-mediated activation of matrix metalloproteinase (MMP)-2 and MMP-9. Cancer Res 2006; 66:10902-10910.
15. Saigal B, Glisson BS, Johnson FM. Dose-dependent and sequence-dependent cytotoxicity of erlotinib and docetaxel in head and neck squamous cell carcinoma. Anticancer Drugs 2008; 19:465-475.
16. Okutucu B, Dincer A, Habib O, Zihnioglu F. Comparison of five methods for determination of total plasma protein concentration. J Biochem Biophys Methods 2007; 70:709-711.
17. Dua P, Gude RP. Pentoxifylline impedes migration in B16F10 melanoma by modulating Rho GTPase activity and actin organisation. Eur J Cancer 2008; 44:1587-1595.
18. Lee GY, Park K, Kim SY, Byun Y. MMPs-specific PEGylated peptide-DOX conjugate micelles that can contain free doxorubicin. Eur J Pharm Biopharm 2007; 67:646-654.
19. Mendes O, Kim HT, Stoica G. Expression of MMP2, MMP9 and MMP3 in breast cancer brain metastasis in a rat model. Clin Exp Metastasis 2005; 22:237-246.
20. Sood AK, Bhatty R, Kamat AA, Lande CN, Han L, Thaker PH, et al. Stress hormone-mediated invasion of ovarian cancer cells. Clin Cancer Res 2006; 12:369-375.
21. Osinsky SP, Ganusevich II, Bubnovskaya LN, Valkovskava NV, Kovelskaya AV, Sergienko TK, et al. Hypoxia level and matrix metalloproteinases-2 and -9 activity in Lewis lung carcinoma: correlation with metastasis. Exp Oncol 2005; 27:202-205.
22. Whittaker M, Floyd CD, Brown P, Gearing AJ. Design and therapeutic application of matrix metalloproteinase inhibitors. Chem Rev 1999; 99:2735-2776.
23. Li YL, Xu WF. Design, synthesis, and activity of caffeoyl pyrrolidine derivatives as potential gelatinase inhibitors. Bioorg Med Chem 2004; 12:5171-5180.
24. Rowsell S, Hawtin P, Minshull CA, Jepson H, Brockbank SM, Barratt DC, et al. Crystal structure of human MMP9 in complex with a reverse hydroxamate inhibitor. J Mol Biol 2002; 319:173-181.
25. Cho YH, Kim JH, Sim GS, Lee BC, Pyo HB, Park HD. Inhibitory effects of antioxidant constituents from Melothria heterophylla on matrix metalloproteinase-1 expression in UVA-irradiated human dermal fibroblasts. J Cosmet Sci 2006; 57:279-289.
26. Sazuka M, Imazawa H, Shoji Y, Mita T, Hara Y, Isemura M. Inhibition of collagenases from mouse lung carcinoma cells by green tea catechins and black tea theaflavins. Biosci Biotechnol Biochem 1997; 61:1504-1506.
27. Tanimura S, Kadomoto R, Tanaka T, Zhang YJ, Kouno I, Kohno M. Suppression of tumor cell invasiveness by hydrolyzable tannins (plant polyphenols) via the inhibition of matrix metalloproteinase-2/-9 activity. Biochem Biophys Res Commun 2005; 330:1306-1313.
28. Li X, Li YL, Xu W. Design, synthesis, and evaluation of novel galloyl pyrrolidine derivatives as potential anti-tumor agents. Bioorg Med Chem 2006; 14:1287-1293.